HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bianchi, D. W. Articles by van der Schoot, C. E. Search for Related Content PubMed PubMed Citation Articles by Bianchi, D. W. Articles by van der Schoot, C. E.

Noninvasive Prenatal Diagnosis of Fetal Rhesus D

Ready for Prime(r) Time

From the ¹Division of Genetics, Department of Pediatrics, Tufts-New England Medical Center, Boston, Massachusetts; ²Center for Research in Biomedicine, University of the West of England, Bristol, United Kingdom; ³Molecular Biology Laboratory, Prenatal Diagnosis Center, American Hospital of Paris, Neuilly, France; and ⁴Experimental Immunohematology, Sanquin Research at CLB, Amsterdam, the Netherlands.

Rhesus (Rh) D blood group incompatibility between the pregnant woman and her fetus is a significant problem due to the possibility of maternal alloimmunization and consequent hemolytic disease of the newborn. The RhD-negative blood group is found in 15% of whites, 3–5% of black Africans, and is rare in Asians. Advances in both our understanding of the RHD locus and its variants, as well as technical improvements in the extraction and amplification of cell-free fetal DNA in maternal plasma, have led to incorporation of noninvasive diagnosis of RHD genotype into routine prenatal care in the United Kingdom, France, and the Netherlands. In this commentary we examine the experience to date with large-scale clinical trials performed in the European Union, describe approaches to reduce false-positive and false-negative results, and review ongoing research to standardize assays and reduce costs using automated assays. False-negative cases are mainly due to either a lack of fetal DNA in the maternal sample due to early gestation or insensitive methods. False-positive cases are due to genotypic variants observed in individuals of African ancestry. Noninvasive prenatal diagnosis of fetal Rhesus D genotype is sensitive and accurate and has been widely validated in Europe. The United States should begin to undertake clinical trials to bring this technology to patient care as soon as possible.

This article has been cited by other articles:

				N. A Murray and I. A G Roberts Haemolytic disease of the newborn Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2007; 92(2): F83 - F88. [Full Text] [PDF]

				K.C. A. Chan, C. Ding, A. Gerovassili, S. W. Yeung, R. W.K. Chiu, T. N. Leung, T. K. Lau, S. S.C. Chim, G. T.Y. Chung, K. H. Nicolaides, et al. Hypermethylated RASSF1A in Maternal Plasma: A Universal Fetal DNA Marker that Improves the Reliability of Noninvasive Prenatal Diagnosis Clin. Chem., December 1, 2006; 52(12): 2211 - 2218. [Abstract] [Full Text] [PDF]